N-Methyl-2-[[3-[2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide (BioDeep_00000172043)
human metabolite blood metabolite
代谢物信息卡片
N-Methyl-2-({3-[2-(pyridin-2-yl)ethenyl]-2H-indazol-6-yl}sulphanyl)benzene-1-carboximidic acid
化学式: C22H18N4OS (386.1201258)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CNC(=O)C1=CC=CC=C1SC1=CC2=C(C=C1)C(C=CC1=CC=CC=N1)=NN2
InChI: InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)
描述信息
同义名列表
5 个代谢物同义名
N-Methyl-2-({3-[2-(pyridin-2-yl)ethenyl]-2H-indazol-6-yl}sulphanyl)benzene-1-carboximidic acid; N-Methyl-2-({3-[2-(pyridin-2-yl)ethenyl]-2H-indazol-6-yl}sulphanyl)benzene-1-carboximidate; N-Methyl-2-({3-[2-(pyridin-2-yl)ethenyl]-2H-indazol-6-yl}sulfanyl)benzene-1-carboximidate; N-methyl-2-({3-[2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide; N-methyl-2-[[3-[2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- E R Kessler, D W Bowles, T W Flaig, E T Lam, A Jimeno. Axitinib, a new therapeutic option in renal cell carcinoma.
Drugs of today (Barcelona, Spain : 1998).
2012 Oct; 48(10):633-44. doi:
10.1358/dot.2012.48.10.1860768. [PMID: 23110259] - Roger B Cohen, Stéphane Oudard. Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities.
Investigational new drugs.
2012 Oct; 30(5):2066-79. doi:
10.1007/s10637-012-9796-8. [PMID: 22327313] - Aline Guillot, Antonin Levy, Cécile Pacaut, Olivier Collard, Christophe Massard, Yacine Merrouche, Nicolas Magné. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.
Clinical genitourinary cancer.
2012 Sep; 10(3):147-52. doi:
10.1016/j.clgc.2012.05.002. [PMID: 22796529] - C Porta, G Tortora, C Linassier, K Papazisis, A Awada, D Berthold, J P Maroto, T Powles, M De Santis. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.
Medical oncology (Northwood, London, England).
2012 Sep; 29(3):1896-907. doi:
10.1007/s12032-011-0016-8. [PMID: 21735145] - Z Mihaly, Z Sztupinszki, P Surowiak, B Gyorffy. A comprehensive overview of targeted therapy in metastatic renal cell carcinoma.
Current cancer drug targets.
2012 Sep; 12(7):857-72. doi:
10.2174/156800912802429265. [PMID: 22515521] - José Luís González Larriba, Enrique Espinosa, Icíar García Carbonero, Javier García-Donas, María López, Andrés Meana, Javier Puente, Joaquim Bellmunt. Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.
Cancer metastasis reviews.
2012 Sep; 31 Suppl 1(?):S11-7. doi:
10.1007/s10555-012-9354-z. [PMID: 22674353] - Sylvie Négrier, Eric Raymond. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.
Investigational new drugs.
2012 Aug; 30(4):1791-801. doi:
10.1007/s10637-011-9677-6. [PMID: 21573959] - Guru Sonpavde, Joaquim Bellmunt, Fabio Schutz, Toni K Choueiri. The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients.
Current oncology reports.
2012 Aug; 14(4):295-306. doi:
10.1007/s11912-012-0237-9. [PMID: 22532265] - Makoto Daimon, Tomoyuki Kato, Wataru Kaino, Kaoru Takase, Shigeru Karasawa, Kiriko Wada, Wataru Kameda, Shinji Susa, Toshihide Oizumi, Yoshihiko Tomita, Takeo Kato. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Japanese journal of clinical oncology.
2012 Aug; 42(8):742-7. doi:
10.1093/jjco/hys076. [PMID: 22628612] - Matteo Santoni, Mimma Rizzo, Luciano Burattini, Valerio Farfariello, Rossana Berardi, Giorgio Santoni, Giacomo Carteni, Stefano Cascinu. Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity.
Recent patents on anti-infective drug discovery.
2012 Aug; 7(2):104-10. doi:
10.2174/157489112801619719. [PMID: 22630822] - Yazdi K Pithavala, Ying Chen, Melvin Toh, Paulina Selaru, Robert R LaBadie, May Garrett, Brian Hee, Janessa Mount, Grace Ni, Karen J Klamerus, Michael A Tortorici. Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.
Cancer chemotherapy and pharmacology.
2012 Jul; 70(1):103-12. doi:
10.1007/s00280-012-1888-9. [PMID: 22644797] - NULL. Axitinib (Inlyta) for advanced renal cell carcinoma.
The Medical letter on drugs and therapeutics.
2012 Jun; 54(1392):47-8. doi:
NULL. [PMID: 22683928] - Yutaka Fujiwara, Naomi Kiyota, Naoko Chayahara, Akiyuki Suzuki, Yoshiko Umeyama, Toru Mukohara, Hironobu Minami. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.
Investigational new drugs.
2012 Jun; 30(3):1055-64. doi:
10.1007/s10637-011-9637-1. [PMID: 21301929] - Thomas Powles. Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns.
Clinical genitourinary cancer.
2012 Jun; 10(2):67-8. doi:
10.1016/j.clgc.2012.04.001. [PMID: 22608779] - Meghan Brennan, J Andrew Williams, Ying Chen, Michael Tortorici, Yazdi Pithavala, Yingxue Cathy Liu. Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics.
European journal of clinical pharmacology.
2012 May; 68(5):645-55. doi:
10.1007/s00228-011-1171-8. [PMID: 22170007] - Giuseppe Lombardi, Fable Zustovich, Martin Donach, Maurizia Dalla Palma, Ornella Nicoletto, Davide Pastorelli. An update on targeted therapy in metastatic renal cell carcinoma.
Urologic oncology.
2012 May; 30(3):240-6. doi:
10.1016/j.urolonc.2009.12.018. [PMID: 20456985] - Courtney Carmichael, Clayton Lau, David Y Josephson, Sumanta K Pal. Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.
Clinical advances in hematology & oncology : H&O.
2012 May; 10(5):307-14. doi:
NULL. [PMID: 22706540] - B Benjamin, M Sahu, U Bhatnagar, D Abhyankar, N R Srinivas. The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors. Can this be used as a prospective guide for the development of novel compounds?.
Arzneimittel-Forschung.
2012 Apr; 62(4):194-201. doi:
10.1055/s-0031-1299772. [PMID: 22290114] - Sumanta Kumar Pal, Stephen Williams, David Y Josephson, Courtney Carmichael, Nicholas J Vogelzang, David I Quinn. Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm.
Molecular cancer therapeutics.
2012 Mar; 11(3):526-37. doi:
10.1158/1535-7163.mct-11-0806. [PMID: 22351744] - Giuseppe Di Lorenzo, Matteo Ferro, Carlo Buonerba. How to carry out retrospective studies in metastatic renal cell cancer: two caveats that should be avoided.
Expert review of anticancer therapy.
2012 Mar; 12(3):331-3. doi:
10.1586/era.11.215. [PMID: 22369324] - Edwin M Posadas, Robert A Figlin. Systemic therapy in renal cell carcinoma: advancing paradigms.
Oncology (Williston Park, N.Y.).
2012 Mar; 26(3):290-301. doi:
NULL. [PMID: 22545314] - Yazdi K Pithavala, Warren Tong, Janessa Mount, Sadayappan V Rahavendran, May Garrett, Brian Hee, Paulina Selaru, Nenad Sarapa, Karen J Klamerus. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.
Investigational new drugs.
2012 Feb; 30(1):273-81. doi:
10.1007/s10637-010-9511-6. [PMID: 20740300] - Marine Gross-Goupil, Christophe Massard, Alain Ravaud. Targeted therapies in metastatic renal cell carcinoma: overview of the past year.
Current urology reports.
2012 Feb; 13(1):16-23. doi:
10.1007/s11934-011-0232-y. [PMID: 22139625] - Guru Sonpavde, Toni K Choueiri, Bernard Escudier, Vincenzo Ficarra, Thomas E Hutson, Peter F Mulders, Jean-Jacques Patard, Brian I Rini, Michael Staehler, Cora N Sternberg, Christian G Stief. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?.
European urology.
2012 Feb; 61(2):307-16. doi:
10.1016/j.eururo.2011.10.032. [PMID: 22055147] - Brian Patson, Roger B Cohen, Anthony J Olszanski. Pharmacokinetic evaluation of axitinib.
Expert opinion on drug metabolism & toxicology.
2012 Feb; 8(2):259-70. doi:
10.1517/17425255.2012.652947. [PMID: 22248343] - Claude Linassier, Delphine Carmier, Pierre Combe, Benjamin Faivre D'Arcier, Franck Bruyere, Berangere Narciso. Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report.
Anticancer research.
2012 Feb; 32(2):697-700. doi:
NULL. [PMID: 22287765] - Brian Shuch, Srinivas Vourganti, Julia C Friend, Lee M Zehngebot, W Marston Linehan, Ramaprasad Srinivasan. Targeting the mTOR pathway in Chromophobe Kidney Cancer.
Journal of Cancer.
2012; 3(?):152-7. doi:
10.7150/jca.4378. [PMID: 22481981] - Bin Wu, Baijun Dong, Yuejuan Xu, Qiang Zhang, Jinfang Shen, Huafeng Chen, Wei Xue. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting.
PloS one.
2012; 7(3):e32530. doi:
10.1371/journal.pone.0032530. [PMID: 22412884] - M E M Dolman, Stefan Harmsen, Ebel H E Pieters, Rolf W Sparidans, Marie Lacombe, Bálint Szokol, László Orfi, György Kéri, Gert Storm, Wim E Hennink, Robbert J Kok. Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells.
International journal of nanomedicine.
2012; 7(?):417-33. doi:
10.2147/ijn.s26485. [PMID: 22334775] - Caroline Hilmi, Mélanie Guyot, Gilles Pagès. VEGF spliced variants: possible role of anti-angiogenesis therapy.
Journal of nucleic acids.
2012; 2012(?):162692. doi:
10.1155/2012/162692. [PMID: 22013509] - Ronald M Bukowski. Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma.
Frontiers in oncology.
2012; 2(?):13. doi:
10.3389/fonc.2012.00013. [PMID: 22655261] - Robin M J M van Geel, Jos H Beijnen, Jan H M Schellens. Concise drug review: pazopanib and axitinib.
The oncologist.
2012; 17(8):1081-9. doi:
10.1634/theoncologist.2012-0055. [PMID: 22733795] - Xiaoen Wang, Liang Zhang, S Nahum Goldberg, Manoj Bhasin, Victoria Brown, David C Alsop, Sabina Signoretti, James W Mier, Michael B Atkins, Rupal S Bhatt. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
Journal of translational medicine.
2011 Dec; 9(?):220. doi:
10.1186/1479-5876-9-220. [PMID: 22188900] - Axel Bex, John Haanen. Tilting the AXIS towards therapeutic limits in renal cancer.
Lancet (London, England).
2011 Dec; 378(9807):1898-900. doi:
10.1016/s0140-6736(11)61655-3. [PMID: 22056245] - Brian I Rini, Bernard Escudier, Piotr Tomczak, Andrey Kaprin, Cezary Szczylik, Thomas E Hutson, M Dror Michaelson, Vera A Gorbunova, Martin E Gore, Igor G Rusakov, Sylvie Negrier, Yen-Chuan Ou, Daniel Castellano, Ho Yeong Lim, Hirotsugu Uemura, Jamal Tarazi, David Cella, Connie Chen, Brad Rosbrook, Sinil Kim, Robert J Motzer. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Lancet (London, England).
2011 Dec; 378(9807):1931-9. doi:
10.1016/s0140-6736(11)61613-9. [PMID: 22056247] - Michael A Tortorici, Melvin Toh, S V Rahavendran, Robert R Labadie, Christine W Alvey, Thomas Marbury, Ernesto Fuentes, Matthew Green, Grace Ni, Brian Hee, Yazdi K Pithavala. Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics.
Investigational new drugs.
2011 Dec; 29(6):1370-80. doi:
10.1007/s10637-010-9477-4. [PMID: 20596748] - John Fruehauf, Jose Lutzky, David McDermott, Charles K Brown, Jean-Baptiste Meric, Brad Rosbrook, David R Shalinsky, Katherine F Liau, Andreas G Niethammer, Sinil Kim, Olivier Rixe. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011 Dec; 17(23):7462-9. doi:
10.1158/1078-0432.ccr-11-0534. [PMID: 21976544] - José M Gómez Sáez. Diagnostic and prognostic markers in differentiated thyroid cancer.
Current genomics.
2011 Dec; 12(8):597-608. doi:
10.2174/138920211798120826. [PMID: 22654559] - Chris Coppin, Christian Kollmannsberger, Lyly Le, Franz Porzsolt, Timothy J Wilt. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
BJU international.
2011 Nov; 108(10):1556-63. doi:
10.1111/j.1464-410x.2011.10629.x. [PMID: 21952069] - Y Chen, J Jiang, J Zhang, M A Tortorici, Y K Pithavala, L Lu, G Ni, P Hu. A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers.
International journal of clinical pharmacology and therapeutics.
2011 Nov; 49(11):679-87. doi:
10.5414/cp201570. [PMID: 22011693] - Yoshihiko Tomita, Hirotsugu Uemura, Hiroyuki Fujimoto, Hiro-omi Kanayama, Nobuo Shinohara, Hayakazu Nakazawa, Keiji Imai, Yoshiko Umeyama, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
European journal of cancer (Oxford, England : 1990).
2011 Nov; 47(17):2592-602. doi:
10.1016/j.ejca.2011.07.014. [PMID: 21889330] - Thai H Ho, Eric Jonasch. Axitinib in the treatment of metastatic renal cell carcinoma.
Future oncology (London, England).
2011 Nov; 7(11):1247-53. doi:
10.2217/fon.11.107. [PMID: 22044199] - Giuseppe Procopio, Elena Verzoni, Roberto Iacovelli, Valentina Guadalupi, Francesco Gelsomino, Roberto Buzzoni. Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience.
Expert review of anticancer therapy.
2011 Nov; 11(11):1631-40. doi:
10.1586/era.11.154. [PMID: 22050012] - Peter C Trask, Andrew G Bushmakin, Joseph C Cappelleri, Jamal Tarazi, Brad Rosbrook, Paul Bycott, Sinil Kim, Walter M Stadler, Brian Rini. Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
Journal of cancer survivorship : research and practice.
2011 Sep; 5(3):255-62. doi:
10.1007/s11764-011-0178-6. [PMID: 21476015] - Sumanta Kumar Pal, Nicholas J Vogelzang. Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS.
Clinical genitourinary cancer.
2011 Sep; 9(1):3-5. doi:
10.1016/j.clgc.2011.06.003. [PMID: 21816688] - Laurence Albiges, Mohamed Salem, Brian Rini, Bernard Escudier. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Hematology/oncology clinics of North America.
2011 Aug; 25(4):813-33. doi:
10.1016/j.hoc.2011.04.006. [PMID: 21763969] - Stéphane Bouchet, Emmanuelle Chauzit, Dominique Ducint, Nadège Castaing, Mireille Canal-Raffin, Nicholas Moore, Karine Titier, Mathieu Molimard. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS.
Clinica chimica acta; international journal of clinical chemistry.
2011 May; 412(11-12):1060-7. doi:
10.1016/j.cca.2011.02.023. [PMID: 21345336] - Brian I Rini, Darrel P Cohen, Dongrui R Lu, Isan Chen, Subramanian Hariharan, Martin E Gore, Robert A Figlin, Michael S Baum, Robert J Motzer. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Journal of the National Cancer Institute.
2011 May; 103(9):763-73. doi:
10.1093/jnci/djr128. [PMID: 21527770] - Birk Poller, Dilek Iusuf, Rolf W Sparidans, Els Wagenaar, Jos H Beijnen, Alfred H Schinkel. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
Drug metabolism and disposition: the biological fate of chemicals.
2011 May; 39(5):729-35. doi:
10.1124/dmd.110.037317. [PMID: 21282407] - Yutaka Ueda, Tatsu Shimoyama, Haruyasu Murakami, Noboru Yamamoto, Yasuhide Yamada, Hitoshi Arioka, Tomohide Tamura. Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology.
2011 May; 67(5):1101-9. doi:
10.1007/s00280-010-1404-z. [PMID: 20676675] - Liang Zhang, Manoj Bhasin, Rachel Schor-Bardach, Xiaoen Wang, Michael P Collins, David Panka, Prabhakar Putheti, Sabina Signoretti, David C Alsop, Towia Libermann, Michael B Atkins, James W Mier, S Nahum Goldberg, Rupal S Bhatt. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.
PloS one.
2011 Apr; 6(4):e19144. doi:
10.1371/journal.pone.0019144. [PMID: 21559452] - Anthony W Tolcher, Leonard J Appleman, Geoffrey I Shapiro, Alain C Mita, Frank Cihon, Arthur Mazzu, Pavur R Sundaresan. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.
Cancer chemotherapy and pharmacology.
2011 Apr; 67(4):751-64. doi:
10.1007/s00280-010-1372-3. [PMID: 20521052] - Pankaj Bhargava, Murray O Robinson. Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
Current oncology reports.
2011 Apr; 13(2):103-11. doi:
10.1007/s11912-011-0154-3. [PMID: 21318618] - Francesco Perri, Giuseppe Di Lorenzo, Giuseppina Della Vittoria Scarpati, Carlo Buonerba. Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.
World journal of clinical oncology.
2011 Mar; 2(3):150-7. doi:
10.5306/wjco.v2.i3.150. [PMID: 21611089] - Charles Faselis, Michael Doumas, Vasilios Papademetriou. Common secondary causes of resistant hypertension and rational for treatment.
International journal of hypertension.
2011 Mar; 2011(?):236239. doi:
10.4061/2011/236239. [PMID: 21423678] - T Powles, S Chowdhury, R Jones, M Mantle, P Nathan, A Bex, L Lim, T Hutson. Sunitinib and other targeted therapies for renal cell carcinoma.
British journal of cancer.
2011 Mar; 104(5):741-5. doi:
10.1038/sj.bjc.6606061. [PMID: 21266975] - M E Gore, J M G Larkin. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.
British journal of cancer.
2011 Feb; 104(3):399-406. doi:
10.1038/sj.bjc.6606084. [PMID: 21285971] - Sandra Steffens, Viktor Grünwald, Kristina I Ringe, Christoph Seidel, Hendrik Eggers, Mark Schrader, Frank Wacker, Markus A Kuczyk, Andres J Schrader. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?.
The oncologist.
2011; 16(11):1565-71. doi:
10.1634/theoncologist.2011-0213. [PMID: 22020210] - Bernard Escudier, Martin Gore. Axitinib for the management of metastatic renal cell carcinoma.
Drugs in R&D.
2011; 11(2):113-26. doi:
10.2165/11591240-000000000-00000. [PMID: 21679004] - Viktor Gruenwald, Gernot Beutel, Susanne Schuch-Jantsch, Christoph Reuter, Philipp Ivanyi, Arnold Ganser, Marion Haubitz. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib.
BMC cancer.
2010 Dec; 10(?):695. doi:
10.1186/1471-2407-10-695. [PMID: 21194438] - Robert Goldstein, Lisa Pickering, James Larkin. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?.
Expert review of anticancer therapy.
2010 Oct; 10(10):1545-57. doi:
10.1586/era.10.134. [PMID: 20942625] - Manuela Schmidinger, Joaquim Bellmunt. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.
Cancer treatment reviews.
2010 Aug; 36(5):416-24. doi:
10.1016/j.ctrv.2010.01.003. [PMID: 20163917] - Michael M Vickers, Toni K Choueiri, Miranda Rogers, Andrew Percy, Daygen Finch, Ivan Zama, Tina Cheng, Scott North, Jennifer J Knox, Christian Kollmannsberger, David F McDermott, Brian I Rini, Daniel Y Heng. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy.
Urology.
2010 Aug; 76(2):430-4. doi:
10.1016/j.urology.2009.12.031. [PMID: 20223508] - Ron J Keizer, Anubha Gupta, Melvin R Mac Gillavry, Mendel Jansen, Jantien Wanders, Jos H Beijnen, Jan H M Schellens, Mats O Karlsson, Alwin D R Huitema. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.
Journal of pharmacokinetics and pharmacodynamics.
2010 Aug; 37(4):347-63. doi:
10.1007/s10928-010-9164-2. [PMID: 20652729] - Astrid A M van der Veldt, Martijn R Meijerink, Alfons J M van den Eertwegh, Epie Boven. Targeted therapies in renal cell cancer: recent developments in imaging.
Targeted oncology.
2010 Jun; 5(2):95-112. doi:
10.1007/s11523-010-0146-5. [PMID: 20625845] - A F Vozianov, A K Butenko, K P Zak. [Task-orientated therapy (target-therapy) directed to patients with renal cell carcinoma].
Likars'ka sprava.
2010 Apr; ?(3-4):3-11. doi:
. [PMID: 21268291] - Toru Mukohara, Hikaru Nakajima, Hirofumi Mukai, Shunji Nagai, Kuniaki Itoh, Yoshiko Umeyama, Junichi Hashimoto, Hironobu Minami. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients.
Cancer science.
2010 Apr; 101(4):963-8. doi:
10.1111/j.1349-7006.2009.01465.x. [PMID: 20180805] - A A M van der Veldt, M R Meijerink, A J M van den Eertwegh, J B A G Haanen, E Boven. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
British journal of cancer.
2010 Mar; 102(5):803-9. doi:
10.1038/sj.bjc.6605567. [PMID: 20145618] - J Ansari, J Glaholm, R McMenemin, N D James, S A Hussain. Recent advances and future directions in the management of metastatic renal cell carcinoma.
Anti-cancer agents in medicinal chemistry.
2010 Mar; 10(3):225-35. doi:
10.2174/1871520611009030225. [PMID: 20184547] - Alvaro Yogi, Sarah E O'Connor, Glaucia E Callera, Rita C Tostes, Rhian M Touyz. Receptor and nonreceptor tyrosine kinases in vascular biology of hypertension.
Current opinion in nephrology and hypertension.
2010 Mar; 19(2):169-76. doi:
10.1097/mnh.0b013e3283361c24. [PMID: 20051848] - Y K Pithavala, M Tortorici, M Toh, M Garrett, B Hee, U Kuruganti, G Ni, K J Klamerus. Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.
Cancer chemotherapy and pharmacology.
2010 Feb; 65(3):563-70. doi:
10.1007/s00280-009-1065-y. [PMID: 19603168] - S Sharma, V Abhyankar, R E Burgess, J Infante, R C Trowbridge, J Tarazi, S Kim, M Tortorici, Y Chen, R L Robles. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology.
2010 Feb; 21(2):297-304. doi:
10.1093/annonc/mdp489. [PMID: 19940012] - N Murukesh, C Dive, G C Jayson. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.
British journal of cancer.
2010 Jan; 102(1):8-18. doi:
10.1038/sj.bjc.6605483. [PMID: 20010945] - Hassane Izzedine, Christophe Massard, Jean Philippe Spano, François Goldwasser, David Khayat, Jean Charles Soria. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
European journal of cancer (Oxford, England : 1990).
2010 Jan; 46(2):439-48. doi:
10.1016/j.ejca.2009.11.001. [PMID: 20006922] - Cristina Suárez, Rafael Morales, Eva Muñoz, Jordi Rodón, Claudia M Valverde, Joan Carles. Molecular basis for the treatment of renal cell carcinoma.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
2010 Jan; 12(1):15-21. doi:
10.1007/s12094-010-0461-4. [PMID: 20080466] - James M G Larkin, Lynda M Pyle, Martin E Gore. Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies.
The oncologist.
2010; 15(11):1135-46. doi:
10.1634/theoncologist.2010-0078. [PMID: 21051659] - Rolf W Sparidans, Dilek Iusuf, Alfred H Schinkel, Jan H M Schellens, Jos H Beijnen. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2009 Dec; 877(32):4090-6. doi:
10.1016/j.jchromb.2009.10.024. [PMID: 19910267] - J L Perez-Gracia, C Prior, F Guillén-Grima, V Segura, A Gonzalez, A Panizo, I Melero, E Grande-Pulido, A Gurpide, I Gil-Bazo, A Calvo. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array.
British journal of cancer.
2009 Dec; 101(11):1876-83. doi:
10.1038/sj.bjc.6605409. [PMID: 19904265] - David Cella. Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes.
Cancer treatment reviews.
2009 Dec; 35(8):733-7. doi:
10.1016/j.ctrv.2009.07.003. [PMID: 19699588] - Giuseppe Di Lorenzo, Riccardo Autorino, Cora N Sternberg. Metastatic renal cell carcinoma: recent advances in the targeted therapy era.
European urology.
2009 Dec; 56(6):959-71. doi:
10.1016/j.eururo.2009.09.002. [PMID: 19748725] - Nicola L Ainsworth, Jean Sz Lee, Tim Eisen. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
Expert review of anticancer therapy.
2009 Dec; 9(12):1793-805. doi:
10.1586/era.09.144. [PMID: 19954291] - Gaetano Facchini, Francesco Perri, Michele Caraglia, Carmela Pisano, Stefano Striano, Luigi Marra, Francesco Fiore, Pasquale Aprea, Sandro Pignata, Rosario Vincenzo Iaffaioli. New treatment approaches in renal cell carcinoma.
Anti-cancer drugs.
2009 Nov; 20(10):893-900. doi:
10.1097/cad.0b013e32833123d4. [PMID: 19752718] - H S Wasan, G M Springett, C Chodkiewicz, R Wong, J Maurel, C Barone, B Rosbrook, A D Ricart, S Kim, J-P Spano. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.
British journal of cancer.
2009 Oct; 101(7):1162-7. doi:
10.1038/sj.bjc.6605243. [PMID: 19724276] - Masahiro Sugawara, David L Geffner, Dorothy Martinez, Jerome M Hershman. Novel treatment of medullary thyroid cancer.
Current opinion in endocrinology, diabetes, and obesity.
2009 Oct; 16(5):367-72. doi:
10.1097/med.0b013e3283304f0c. [PMID: 19633548] - Brian I Rini, George Wilding, Gary Hudes, Walter M Stadler, Sinil Kim, Jamal Tarazi, Brad Rosbrook, Peter C Trask, Laura Wood, Janice P Dutcher. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009 Sep; 27(27):4462-8. doi:
10.1200/jco.2008.21.7034. [PMID: 19652060] - Michael B Atkins, Toni K Choueiri, Daniel Cho, Meredith Regan, Sabina Signoretti. Treatment selection for patients with metastatic renal cell carcinoma.
Cancer.
2009 May; 115(10 Suppl):2327-33. doi:
10.1002/cncr.24231. [PMID: 19402069] - Brian I Rini. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Cancer.
2009 May; 115(10 Suppl):2306-12. doi:
10.1002/cncr.24227. [PMID: 19402073] - Yoichi Mizutani. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
International journal of urology : official journal of the Japanese Urological Association.
2009 May; 16(5):444-8. doi:
10.1111/j.1442-2042.2009.02277.x. [PMID: 19298634] - Laurence Bastien, Stéphane Culine, Bernard Paule, Souhil Ledbai, Jean Jacques Patard, Alexandre de la Taille. Targeted therapies in metastatic renal cancer in 2009.
BJU international.
2009 May; 103(10):1334-42. doi:
10.1111/j.1464-410x.2009.08454.x. [PMID: 19338565] - Ingrid Alexandre, Bertrand Billemont, Jean Baptiste Meric, Stephane Richard, Olivier Rixe. Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009 Jan; 27(3):472-3; author reply 473. doi:
10.1200/jco.2008.20.1087. [PMID: 19075253] - Daniel Y C Heng, Ronald M Bukowski. Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.
Current cancer drug targets.
2008 Dec; 8(8):676-82. doi:
10.2174/156800908786733450. [PMID: 19075590] - Ezra E W Cohen, Lee S Rosen, Everett E Vokes, Merrill S Kies, Arlene A Forastiere, Francis P Worden, Madeleine A Kane, Eric Sherman, Sinil Kim, Paul Bycott, Michael Tortorici, David R Shalinsky, Katherine F Liau, Roger B Cohen. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2008 Oct; 26(29):4708-13. doi:
10.1200/jco.2007.15.9566. [PMID: 18541897] - Bhanu K Vakkalanka, Ronald M Bukowski. Novel drugs for renal cell carcinoma.
Expert opinion on investigational drugs.
2008 Oct; 17(10):1501-16. doi:
10.1517/13543784.17.10.1501. [PMID: 18808310] - M Staehler, N Haseke, K Zilinberg, T Stadler, A Karl, C G Stief. [Systemic therapy of metastasizing renal cell carcinoma].
Der Urologe. Ausg. A.
2008 Oct; 47(10):1357-67. doi:
10.1007/s00120-008-1874-3. [PMID: 18825295] - Toni K Choueiri, Susan A J Vaziri, Erich Jaeger, Paul Elson, Laura Wood, Ish Prasad Bhalla, Eric J Small, Vivian Weinberg, Nancy Sein, Jeff Simko, Ali-Reza Golshayan, Linda Sercia, Ming Zhou, Frederic M Waldman, Brian I Rini, Ronald M Bukowski, Ram Ganapathi. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
The Journal of urology.
2008 Sep; 180(3):860-5; discussion 865. doi:
10.1016/j.juro.2008.05.015. [PMID: 18635227] - Bernard Escudier. Signaling inhibitors in metastatic renal cell carcinoma.
Cancer journal (Sudbury, Mass.).
2008 Sep; 14(5):325-9. doi:
10.1097/ppo.0b013e3181867605. [PMID: 18836338] - Guru Sonpavde, Thomas E Hutson, Brian I Rini. Axitinib for renal cell carcinoma.
Expert opinion on investigational drugs.
2008 May; 17(5):741-8. doi:
10.1517/13543784.17.5.741. [PMID: 18447599] - Peter C Trask, Andrew G Bushmakin, Joseph C Cappelleri, Paul Bycott, Katherine Liau, Sinil Kim. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib.
Acta oncologica (Stockholm, Sweden).
2008; 47(5):843-51. doi:
10.1080/02841860802047395. [PMID: 18568482] - W Marston Linehan. Targeting VEGF receptors in kidney cancer.
The Lancet. Oncology.
2007 Nov; 8(11):956-7. doi:
10.1016/s1470-2045(07)70322-4. [PMID: 17976606]